Mankind Pharma licenses two insulin analogues from China’s Chongqing Chenan
Mankind Pharma has signed an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical to commercialise two insulin degludec-based diabetes treatments in India, widening its injectable diabetes portfolio.
What happened
Mankind Pharma signed an exclusive agreement with China’s Chongqing Chenan Biopharmaceutical to commercialise two insulin degludec-based diabetes treatments in
Key facts
- 2 insulin analogues
Why this matters
This transaction highlights Mankind’s use of cross-border in-licensing to fill portfolio gaps, positioning it to pursue further specialty and chronic-therapy partnerships.
What to watch
- CDSCO approval or registration milestones for the two insulin analogues.
- Disclosure of launch timing, brand names, pricing, and whether products are imported or locally packaged/manufactured.
- Evidence of Mankind expanding diabetes sales-force capacity, cold-chain infrastructure, or endocrinology-focused promotion.
- Competitor price cuts, new insulin biosimilar launches, or patient-support programs from multinational and domestic rivals.
- Early prescription traction, hospital formulary wins, and management commentary on diabetes-segment revenue contribution.
- Seek CDSCO approvals and complete product-registration, labeling, pharmacovigilance, and import/manufacturing compliance steps.
- Build endocrinology, diabetology, hospital, and high-volume clinic targeting around long-acting insulin conversion opportunities.
- Establish cold-chain distribution, inventory forecasting, and reliable supply arrangements with Chongqing Chenan.
- Set launch pricing, patient affordability, physician education, and trade-margin programs against incumbent insulin degludec offerings.
- Pursue formulary, hospital, insurer, and government-channel access where insulin reimbursement and tender demand are material.